BioSpace News Archive

Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for XARACOLL® (bupivacaine hydrochloride collagen-matrix implants), an investigational agent for the management of postsurgical pain after open inguinal hernia surgery.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today reported its consolidated annual financial results for 2019 and provided an update on key achievements, as well as the company’s outlook for its agonist and antagonist immunotherapies for cancers and autoimmune diseases.

The Biotechnology Innovation Organization (BIO) this week hosted a productive virtual summit intended to foster collaboration among key government agencies and biopharmaceutical innovators with one goal: eradicating COVID-19.

Dr. Reddy’s Laboratories Ltd. (along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it is voluntarily recalling four lots (ACB902, ACB903, ACB904, ACB905) of Phytonadione Injectable Emulsion USP, 10 mg/mL, Single-Dose Ampules to the hospital level.

As a response to the COVID-19 crisis, the National Spine Health Foundation has launched a collection of resources offering guidance for those quarantined to their homes at this time

Same-Day, Immediate Orthopaedic Care Helps Patients Avoid Crowds, Wait Times and Exposure in the ER or Urgent Care

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced equity inducement grants to eight new non-officer employees consisting of an aggregate of 63,200 share options.

Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct offering priced at-the-market under Nasdaq rules with several institutional and accredited investors of 18,604,652 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at an effective purchase price of $0.43 per share (or pre-funded warrant).

NeuBase expects to announce pharmacokinetic data in non-human primates and in-vitro pharmacodynamic data for the PATrOL™ platform during the week of March 30th as planned

electroCore, Inc. announced the appointments of three new independent members to its Board of Directors effective April 2, 2020.